Myeloproliferative neoplasms: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• ABL1 0
• JAK 25
• TP53 1
• PDGFR 0
• STAT3 0
• PI3K 0
• ERK 1
• FGFR 1
• FLT3 3
• mTOR 0
• AKT 0
• BCL-2 2
• IDH 3
• JNK 0
• HIF-1 0
• CSF1R 3
• HSP90 0
• MAPK 0
• MEK 2
• AMPK 0
• CD123 0
• CD19 0
• CD38 0
• IL-6 0
• KMT2A 0
• MDM2 0
• MYC 0
• NRF2 0
• PPAR 0
• RAS 0
• RUNX1 0
• ATM 0
• CD33 1
• CD40 0
• CDK4/6 1
• CXCR4 0
• EZH2 0
• G6PD 0
• HDAC 0
• KRAS 0
• NF1 0
• NLRP3 0
• NOTCH1 0
• NPM1 0
• NTRK 0
• PD-1 0
• PD-L1 0
• SGLT2 0
• SIRT1 0
• YAP 0

24 of 58+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Therapeutic restoration of CUX1 in -7/del(7q) acute myeloid leukemia

  University of Chicago· Chicago, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NCI · R21

  Loss of TET2 Promotes Leukemogenesis by Enhancing NPY-Mediated PRC2 Disruption and CTCFL Chromatin Remodeling

  Indiana University Indianapolis· Indianapolis, United States· US$407,543 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R43

  Developing a rapid sterility solution to deliver Time to Detection for autologous CAR-T Cell Therapies

  Mango, Inc.· Los Angeles, United States· US$306,817 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · K99

  The role of TET2 clonal hematopoiesis on solid tumor immunology

  University of Tx Md Anderson Can Ctr· Houston, United States· US$134,974 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  The Role of Cell Competition in Shaping the Clonal Structure of Hematopoiesis

  Washington University· Saint Louis, United States· US$465,749 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Identification of novel genetic regulators governing leukaemic transformation from myeloid proliferative neoplasms (MPN2AML)

  Medizinische Hochschule Hannover· Hannover, Germany· EU contribution €313,395· until Aug 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of CD24 and CD24hi Neutrophils in key co-morbidities associated with the MyeloProliferative Neoplasms (NeutroMPN)

  Universidad de Sevilla· Sevilla, Spain· EU contribution €209,915· until May 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategies (Rewind-MF)

  Universitaetsklinikum Aachen· Aachen, Germany· EU contribution €1,999,313· until Mar 2029

8 of 219 running projects, newest first. Listed amounts together: US$115.5m + €2.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

  NCT03627403· University of Utah· Updated 26 Oct 2026

  “PI and Sponsor decision. Accrual was low and there was sufficient data to detect a response.”Registry text, quoted unchanged. Source

• Withdrawn

  Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera

  NCT06290765· PharmaEssentia· Updated 31 Jul 2026

  “In alignment with company strategic direction.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

  NCT06303193· National Cancer Institute (NCI)· Source

• Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

  NCT07750574· Chengdu Zenitar Biomedical Technology Co., Ltd· Source

• A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

  NCT06773195· Memorial Sloan Kettering Cancer Center· Source

• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

  NCT04717414· Celgene· Source

• Hematological Disorders in EHPVO Patients

  NCT07108023· Rahab Nady· Source

• Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

  NCT06605586· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 1
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 2
• Gene Expression Profiling 14
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 2
• Exome Sequencing 4
• Proteomics 7
• Metabolomics 3
• Mass Spectrometry 2
• Flow Cytometry 19
• Immunohistochemistry 2
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 22
• Magnetic Resonance Imaging 14
• Machine Learning 7
• Deep Learning 3
• Cohort Studies 16
• Genome-Wide Association Study 1

• Longitudinal Single-Cell RNA Sequencing Reveals Evolution of Microstates and Macrostates in Chronic Myeloid Leukemia.

  Cancer Res, Nov 2026

• scDRP: disentangled representation learning for predicting single-cell responses to perturbations and estimating individual treatment effects.

  Brief Bioinform, Sept 2026

• Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

  Blood Adv, Jul 2026

• Clonal Metamorphosis: Deconstructing MPN Evolution with Single-Cell and Spatial Multi-Omics.

  Clin Exp Med, Jun 2026

• High-dimensional spatiotemporal single-cell atlas and 3D imaging of the bone marrow microenvironment during CML progression.

  Blood, May 2026

• Single cell transcriptional evolution of myeloid leukemia of Down syndrome.

  Nat Commun, Apr 2026

• Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses.

  Haematologica, Apr 2026

• Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development.

  Adv Sci (Weinh), Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.